



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Brolucizumab

Cat. No.:	HY-P9973
CAS No.:	1531589-13-5
Target:	VEGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity ($K_D=1.05$ pM). Brolucizumab can be used for the research of cancer ^{[1][2]} .									
In Vitro	Brolucizumab (2683 nM) inhibits VEGF-A112-induced phosphorylation of VEGFR1 in U87MG human glioma cells and of VEGFR2 in ZHE-483-2 GMEC ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.									
In Vivo	<p>Brolucizumab (15 mg/kg; i.p. 5 days per week for 21 or 41 days) slows the growth of mSLK-KSHV xenograft tumors^[2]. Brolucizumab (5-50 mg/kg; i.p. once or twice daily for 28 days) delays in vivo tumor growth in U87MG glioma models^[1]. Brolucizumab (10 mg/kg; i.v.) shows a half-life of 5.4-7.8 minutes for the rapid decline phase and 1.4-1.9 hours for the slow decline phase in mice^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>NSG mice were subcutaneously injected with mSLK-KSHV cell suspension^[2]</td> </tr> <tr> <td>Dosage:</td> <td>15 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p. 5 days per week for 21 or 41 days</td> </tr> <tr> <td>Result:</td> <td>Significantly lowered tumor growth there was no difference in survival between experimental and combined control groups.</td> </tr> </table>		Animal Model:	NSG mice were subcutaneously injected with mSLK-KSHV cell suspension ^[2]	Dosage:	15 mg/kg	Administration:	i.p. 5 days per week for 21 or 41 days	Result:	Significantly lowered tumor growth there was no difference in survival between experimental and combined control groups.
Animal Model:	NSG mice were subcutaneously injected with mSLK-KSHV cell suspension ^[2]									
Dosage:	15 mg/kg									
Administration:	i.p. 5 days per week for 21 or 41 days									
Result:	Significantly lowered tumor growth there was no difference in survival between experimental and combined control groups.									

REFERENCES

[1]. Szabó E, et, al. Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models. *J Pharmacol Exp Ther*. 2018 May;365(2):422-429.

[2]. Eason AB, et, al. DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma. *PLoS One*. 2020 May 14;15(5):e0233116.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA